$SCTX insider trading

Over the last 12 months, Scribe Therapeutics insiders reported 6 buys totaling $71.3M and no sales across SEC Form 4 filings.

$71.3M
6
6
0%
Side
$10K$100K$1.0M$10M$100MJul '26AugSep
Aghazadeh Behzad
GORDON CARL L
ORBIMED ADVISORS LLC
AH Bio Fund II, L.P.
Lucas Svetlana

All insider trades

Scroll the table sideways for price, value and marks.

Jul 28, 2026Aghazadeh Behzad▲ Buy2,391,238$15.16$36.3M+342.8%
Jul 27, 2026AH Bio Fund II, L.P.▲ Buy333,333$15$5.0M+16.2%
Jul 27, 2026GORDON CARL L▲ Buy1,000,000$15$15.0M+286.7%
Jul 27, 2026ORBIMED ADVISORS LLC▲ Buy1,000,000$15$15.0M+286.7%
Jul 23, 2026Lucas Svetlana▲ Buy3,000$15$45K
Jul 23, 2026Parrot David▲ Buy2,666$15$40K

Every $SCTX filing on this page is one API call away

The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Scribe Therapeutics filings can reach your inbox instead.

Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $SCTX feed.

SCTX Insider Trading — Scribe Therapeutics Form 4 Buys & Sells | alphai